Biotech Industry Examiner

Menu
Menu
subscribe now
Search
A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

A pill to live to 150? China’s grapeseed longevity hype gets right — and wrong

Lonvi Biosciences says its procyanidin C1 capsule could, one day,

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

Decoding the 100-Year-Old Code: Inside an Ambitious Quest to Unveil the Genetics of Extreme Longevity

In a world obsessed with youth, some scientists are turning

The FDA wants to “pre-check” factories before the medicine exists

The FDA wants to “pre-check” factories before the medicine exists

Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear

Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear

Obesity’s next arms race: staying power, not just weight loss

Obesity’s next arms race: staying power, not just weight loss

Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

MOST POPULAR

News

The FDA wants to “pre-check” factories before the medicine exists
Obesity’s next arms race: staying power, not just weight loss
The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Amgen’s $840m wager on Dark Blue shows why pharma keeps paying to make proteins disappear
Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top